Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.

Scientific reports - 29 Oct 2020

Marczynski Gabriella Taques, Laus Ana Carolina, Dos Reis Mariana Bisarro, Reis Rui Manuel, Vazquez Vinicius de Lima

Abstract excerpt

BRAF, NRAS and TERT mutations occur in more than 2/3 of melanomas. Its detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for identification and monitoring of metastatic disease. We proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigate whether it was associated to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Limit of Detection

Share to Liquid Biopsy

Share to Melanoma

Share to Skin Neoplasms

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 33122747
DOI: 10.1038/s41598-020-75792-1
PMCID: PMC7596487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.PMID 33122747Read ↗

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNASemantic proximity Read ↗

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studySemantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Semantic proximity Read ↗

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis.Semantic proximity Read ↗

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.